Login to Your Account

The best medicine, prevention, may be coming to cancer

By Anette Breindl
Science Editor

Friday, January 10, 2014
Cancer Prevention Pharmaceuticals Inc. and Swiss specialty pharma company Tillotts Pharma AG, a wholly owned subsidiary of Tokyo-based Zeria Pharmaceutical Co. Ltd., signed a licensing agreement for European and Japanese rights to develop and commercialize CPP-1X/sulindac for the treatment of the orphan disease familial adenomatous polyposis, and other gastrointestinal conditions.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription